The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Henry H WooChi-Ping HuangWilliam J HuangYi-Huei ChangChi-Shun LienArchil ChkhotuaDean S Elterman

Published in: Prostate cancer and prostatic diseases (2022)

Preliminary results demonstrate that the Urocross Expander System is a feasible and safe procedure for treating BPH/LUTS. A strong signal of efficacy justifies further evaluation of this PRostatic Urethral Expansion (PURE) procedure. Negative features of earlier generations of prostatic implants such as biocompatibility, migrations and encrustation have possibly been overcome.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
breast reconstruction
minimally invasive
clinical trial
study protocol
randomized controlled trial
phase ii
combination therapy